Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC) Meeting Abstract
| Authors: | Bellmunt, J.; Mullane, S. A.; Jacobus, S.; Polacek, L.; Takeda, D. Y.; Harshman, L.; Choueiri, T.; Wagle, N.; Van Allen, E. M.; Kantoff, P.; Rosenberg, J. E. |
| Abstract Title: | Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC) |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi271 |
| Language: | English |
| ACCESSION: | WOS:000393912500781 |
| DOI: | 10.1093/annonc/mdw373.13 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 785P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
